Getting to know your drugs

Pertinent practical points

Behavioural emergencies

Delirium

Dementia

Dementia: update

Other organic mental disorders

Alcohol and drug disorders

Schizophrenia

Mood disorders

Anxiety and associated disorders

Sleep disorders

Personality disorders

Eating disorders

Disorders usually first diagnosed in childhood and adolescence

Pregnancy and breastfeeding

Aripiprazole (Abilify) for schizophrenia. Med Lett Drugs Ther 2003;45(1150):15-6.

Buprenorphine: an alternative to methadone. Med Lett Drugs Ther 2003;45(1150):13-5.

Escitalopram (lexapro) for depression. Med Lett Drugs Ther 2002;44(1140):83-4.

Hyponatraemia with SSRIs. Australian Adverse Drug Reactions Bulletin 2003;22(10).

[full-text]

Martindale. The complete drug reference. 33rd ed. London: Pharmaceutical Press; 2002.

Ziprasidone: The latest FDA-approved atypical antipsychotic. International Drug Therapy Newsletter 2001;2001(36):25-30.

Ziprasidone (Geodon) for schizophrenia. Med Lett Drugs Ther 2001;43(1106):51-2.

Ayd F. Akathisia and suicide: fact or myth? An update. International Drug Therapy Newsletter 2001;36:44-8.

Ayd F. Aripiprazole: recent evidence-based clinical data. International Drug Therapy Newsletter 2003;38(33-37).

Bennett DA, Jr., Phun L, Polk JF, Voglino SA, Zlotnik V, Raffa RB. Neuropharmacology of St. John's Wort (Hypericum). Ann Pharmacother 1998;32(11):1201-8.

Bettinger TL, Mendelson SC, Dorson PG, Crismon ML. Olanzapine-induced glucose dysregulation. Ann Pharmacother 2000;34(7-8):865-7.

Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother 2003;37(5):687-94.

Brodeur MR, Stirling AL. Delirium associated with zolpidem. Ann Pharmacother 2001;35(12):1562-4.

Buck M. Amphetamine in the treatment of attention-deficit/hyperactivity disorder. Pediatric Pharmacotherapy 2002; 8(3).

Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 2000;23(3):215-28.

Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. Bmj 2002;325(7376):1332-3.

Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302(1):381-9.

Caley CF CC. Ziprasidone: the fifth atypical antipsychotic. Ann of Pharmacother 2002;2002(36):839-50.

Clayton AH, Zajecka J, Ferguson JM, Filipiak-Reisner JK, Brown MT, Schwartz GE. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol 2003;18(3):151-6.

Crismon ML, DeLeon A, Miller AL. Aripiprazole: does partial dopaminergic agonism translate into clinical benefits? Ann Pharmacother 2003;37(5):738-40.

Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003;163(1):59-64.

de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. Bmj 1999;319(7217):1106-9.

Elming H, Sonne J, Lublin HK. The importance of the QT interval: a review of the literature. Acta Psychiatr Scand 2003;107(2):96-101.

Gelenberg A. Modafinil (Provigil): finding a niche. Biological therapies in psychiatry 2001;24:23.

Gelenberg A. St John's wort for depression. Biological Therapies in Psychiatry 2001;24:33.

Gelenberg A. Antidepressants and hyponatraemia. Biological Therapies in Psychiatry 2002;2002(25):44.

Gelenberg A. Nefazodone hepatotoxicity: black box warning. Biological Therapies in Psychiatry 2002;25:2.

Gelenberg A. SSRIs and SIADH. Biological Therapies in Psychiatry 2003;26:14.

Gelenberg A. SSRIs for children. Biological Therapies in Psychiatry 2003;26:33.

Gelenberg A. SSRIs and GI bleeding. Biological therapies in psychiatry 2003;26:7.

Greeson JM, Sanford B, Monti DA. St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl) 2001;153(4):402-14.

Hall M, Buckley  N. Serotonin syndrome. Aust Prescr 2003;26(3):62-3.

[full text]

Hartmann S, Mobius HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 2003;18(2):81-5.

Hurley SC. Lamotrigine update and its use in mood disorders. Ann Pharmacother 2002;36(5):860-73.

Israel AG, Kramer JA. Safety of zaleplon in the treatment of insomnia. Ann Pharmacother 2002;36(5):852-9.

Jarvis B, Figgitt DP. Memantine. Drugs Aging 2003;20(6):465-76; discussion 77-8.

Jefferson J. Lithium side effects and their management: an update. International Drug Therapy Newsletter 2001;36:81-5.

Jefferson JW GJ, Ackerman DL, Carroll JA. Lithium encylopedia for clinical practice. 2nd ed. Washington: American Psychiatric Press Inc; 1987.

Jefferson JW. Lithium-associated clinical hypothyroidism. International Drug Therapy Newsletter 2000;35:84-6.

Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63(9):763-71.

Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001;158(3):360-9.

Kirby D, Harrigan S, Ames D. Hyponatraemia in elderly psychiatric patients treated with Selective Serotonin Reuptake Inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit. Int J Geriatr Psychiatry 2002;17(3):231-7.

Lecrubier Y. Is amisulpride an 'atypical' atypical antipsychotic agent? Int Clin Psychopharmacol 2000;15 Suppl 4:S21-6.

McRae A LL. Aripiprazole: The latest antipsychotic. International Drug Therapy Newsletter 2003;38:25-30.

Mota Neto JIS LM, Soares BGO. Amisulpride for schizophrenia (Cochrane Review). The Cochrane Library 2003(4).

Overman GP, Teter CJ, Guthrie SK. Acamprosate for the adjunctive treatment of alcohol dependence. Ann Pharmacother 2003;37(7-8):1090-9.

Pearson VE. Galantamine: a new alzheimer drug with a past life. Ann Pharmacother 2001;35(11):1406-13.

Pies R. Antipsychotic medications and the QT Interval. Internationa1 Drug Therapy Newsletter 2001;36:85-8.

Pies R. Pharmacologic Approaches to Psychotropic-Induced Weight Gain. International Drug Therapy Newsletter 2002;37:49-53.

Raisch DW, Fye CL, Boardman KD, Sather MR. Opioid dependence treatment, including buprenorphine/naloxone. Ann Pharmacother 2002;36(2):312-21.

Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348(14):1333-41.

Scates AC, Doraiswamy PM. Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann Pharmacother 2000;34(11):1302-12.

Schatzberg AF CJ, DeBattista C. A Manual of Clinical Psychopharmacology. 4th ed. Washington: American Psychiatric Press Inc; 2003.

Sneed KB, Gonzalez EC. Type 2 diabetes mellitus induced by an atypical antipsychotic medication. J Am Board Fam Pract 2003;16(3):251-4.

Tandon R JM. Suicidal behaviour in schizophrenia: diagnosis, neurobiology, and treatment implications. Curr Opin Psychiatry 2003;16(2):193-7.

Waechter F. Paroxetine must not be given to patients under 18. Bmj 2003;326(7402):1282

Wimo A, Winblad B, Stoffler A, Wirth Y, Mobius HJ. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 2003;21(5):327-40.

Winans EA JP. The role of parenteral antipsychotics in clinical practice - Part I. International Drug Therapy Newsletter 2002;37:17-24.

Winans EA JP. The role of parenteral antipsychotics in clinical practice - Part II. International Drug Therapy Newsletter 2002;2002(37):25-32.

Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14(2):135-46.

Wirshing DA. Adverse effects of atypical antipsychotics. J Clin Psychiatry 2001;62 Suppl 21:7-10.

Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. Cmaj 2002;167(11):1269-70.

Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003;361(9360):799-808.

Gelenberg. Newer antipsychotics may increase pregnancy risk. Biological Therapies in Psychiatry 2002;25:17-8.

Gelenberg. Talking with patients about antidepressants. Biological Therapies in Psychiatry 2002;25:48.

Glassman AH. Clinical management of cardiovascular risks during treatment with psychotropic drugs. J Clin Psychiatry 2002;63 Suppl 9:12-7.

Jaysinghe R, Kovoor P. Drugs and the QTc interval. Aust Prescr 2002;25:63-5.

[full text]

Lawrence DM, Holman CD, Jablensky AV, Hobbs MS. Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980-1998. Br J Psychiatry 2003;182:31-6.

Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. Bmj 2003;327(7417):708-13.

Allen  MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP. The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgrad Med 2001(Spec No):1-88; quiz 9-90.

Ames D, Camm J, Cook P, Falkai P, Gury C, Hurley R, et al. Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group. Australasian Psychiatry 2002;10(2):115-24.

Battaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997;15(4):335-40.

Fitzgerald P. Long-acting antipsychotic medication, restraint and treatment in the management of acute psychosis. Aust N Z J Psychiatry 1999;33(5):660-6.

Forster PL, Buckley R, Phelps MA. Phenomenology and treatment of psychotic disorders in the psychiatric emergency service. Psychiatr Clin North Am 1999;22(4):735-54.

NSW Department of Health. Guidelines for the management of severe behavioural disturbance in adults. 2001.

Shale JH, Shale CM, Mastin WD. A Review of the Safety and Efficacy of Droperidol for the Rapid Sedation of Severely Agitated and Violent Patients. J Clin Psychiatry 2003;64(5):500-5.

Sheline Y, Nelson T. Patient choice: deciding between psychotropic medication and physical restraints in an emergency. Bull Am Acad Psychiatry Law 1993;21(3):321-9.

Trissel L. Handbook on injectable drugs. 9th edition ed. Bethesda: American Society of Health-System Pharmacists; 1996.

Brown  TM, Boyle MF. Delirium. Bmj 2002;325(7365):644-7.

Casarett  DJ, Inouye SK. Diagnosis and management of delirium near the end of life. Ann Intern Med 2001;135(1):32-40.

Cole  MG. Delirium: effectiveness of systematic interventions. Dement Geriatr Cogn Disord 1999;10(5):406-11.

Inouye  SK, Schlesinger MJ, Lydon TJ. Delirium: a symptom of how hospital care is failing older persons and a window to improve quality of hospital care. Am J Med 1999;106(5):565-73.

Meagher  DJ. Delirium: optimising management. Bmj 2001;322(7279):144-9.

Schwartz TL, Masand PS. The role of atypical antipsychotics in the treatment of delirium. Psychosomatics 2002;43(3):171-4.

Sipahimalani A, Masand PS. Use of risperidone in delirium: case reports. Ann Clin Psychiatry 1997;9(2):105-7.

Sipahimalani A, Masand PS. Olanzapine in the treatment of delirium. Psychosomatics 1998;39(5):422-30.

Brodaty  H, Ames D, Boundy KL, Hecker J, Snowdon J, Storey E, et al. Pharmacological treatment of cognitive deficits in Alzheimer's disease. Med J Aust 2001;175(6):324-9.

Doody  RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1154-66.

Folstein  MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189-98.

Henderson  A, Jorm A. Dementia in Australia: Canberra Aged and Community Care Division. Department of Health and Family Services; 1998.

McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356(9247):2031-6.

Molloy  DW, Alemayehu E, Roberts R. Reliability of a Standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination. Am J Psychiatry 1991;148(1):102-5.

O'Brien J, Ames D, Burns A. Dementia. 2nd ed. London: Edward Arnold; 2000.

Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. Cmaj 2002;167(11):1269-70.

Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003;64(2):134-43.

De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2004;19(2):115-26.

De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53(5):946-55.

Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999;60(2):107-15.

Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000;57(10):968-76.

Lishman  W. Organic psychiatry: the psychological consequences of cerebral disorder. Oxford: Blackwell; 1998.

Silver  J, Hales R, Yudofsky S. Neuropsychiatric aspects of traumatic brain injury. In: Yudofsky S, Hales R, editors. American psychiatric publishing textbook of neuropsychiatry and clinical neurosciences. 4th ed. Washington DC: American Psychiatric Press; 2002.

Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001;96(5):683-90.

Bell J, Kimber J, Mattick R, Ali R, Lintzeris N, Monheit B, et al. Interim clinical guidelines - use of naltrexone in relapse prevention for opioid dependence: National Expert Advisory Committee on Illicit Drugs. [Note: this guideline has been updated since the publication of Psychotropic 5].

Copeland J, Swift W, Roffman R, Stephens R. A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J Subst Abuse Treat 2001;21(2):55-64; discussion 5-6.

Degenhardt L, Darke S, Dillon P. The prevalence and correlates of gamma-hydroxybutyrate (GHB) overdose among Australian users. Addiction 2003;98(2):199-204.

Feeney GF, Young RM, Connor JP, Tucker J, McPherson A. Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term treatment outcomes for alcohol dependence improved? Aust N Z J Psychiatry 2002;36(5):622-8.

Fiellin DA, Reid MC, O'Connor PG. New therapies for alcohol problems: application to primary care. Am J Med 2000;108(3):227-37.

Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. Jama 1999;281(14):1318-25.

Gowing LR, Henry-Edwards SM, Irvine RJ, Ali RL. The health effects of ecstasy: a literature review. Drug Alcohol Rev 2002;21(1):53-63.

Graham R, Wodak AD, Whelan G. New pharmacotherapies for alcohol dependence. Med J Aust 2002;177(2):103-7.

Hulse G, White J, Cape G. Management of alcohol and drug problems. Oxford University Press; 2002.

Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000;343(18):1290-7.

Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003;60(1):92-9.

Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001;345(24):1734-9.

Lintzeris N, Clark N, Muhleisen P, Ritter A, Ali R, Bell J, et al. National clinical guidelines and procedures for the use of buprenorphine in the treatment of heroin dependence. Canberra: Department of Health and Aged Care; 2001 March 2001.

[URL]

Milroy CM. Ten years of 'ecstasy'. J R Soc Med 1999;92(2):68-71.

National Health and Medical Research Council. Australian alcohol guidelines: health risks and benefits. Canberra: Commonwealth of Australia; 2001.

Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Addit Contam 2003;20(1):1-30.

Olmedo R, Hoffman RS. Withdrawal syndromes. Emerg Med Clin North Am 2000;18(2):273-88.

Rawson RA, Gonzales R, Brethen P. Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat 2002;23(2):145-50.

Rawson RA, Huber A, McCann M, Shoptaw S, Farabee D, Reiber C, et al. A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Arch Gen Psychiatry 2002;59(9):817-24.

Rickels K, DeMartinis N, Rynn M, Mandos L. Pharmacologic strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol 1999;19(6 Suppl 2):12S-6S.

Roche A et al. Alcohol and other drugs: a handbook for health professionals. Commonwealth Department of Health and Ageing; 2003. (draft currently)

Rochester JA, Kirchner JT. Ecstasy (3,4-methylenedioxymethamphetamine): history, neurochemistry, and toxicology. J Am Board Fam Pract 1999;12(2):137-42.

Smith NT. A review of the published literature into cannabis withdrawal symptoms in human users. Addiction 2002;97(6):621-32.

Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2002(2):CD001867.

Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P. Treatment for amphetamine dependence and abuse. Cochrane Database Syst Rev 2001(4):CD003022.

Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P. Treatment for amphetamine withdrawal. Cochrane Database Syst Rev 2001(4):CD003021.

Thomson AD, Cook CC, Touquet R, Henry JA. The Royal College of Physicians report on alcohol: guidelines for managing Wernicke's encephalopathy in the accident and Emergency Department. Alcohol Alcohol 2002;37(6):513-21.

Turning Point Alcohol and Drug Centre. Prescribing for drug withdrawal; 2002.

Ward J, Mattick R, Hall W. Methadone maintenance treatment and other opioid replacement therapies. 1 ed. Amsterdam: Harwood Academic Publishers; 1998.

Anonymous. Incredibly easy! Giving Z-track injections. Nursing 2002;32(9):81.

Belanger-Annable MC. Long-acting neuroleptics: technique for intramuscular injection. Can Nurse 1985;81(8):41-3.

Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60(6):553-64.

de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry 2003;160(2):303-9.

Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Bmj 2000;321(7273):1371-6.

Geddes J. Generating evidence to inform policy and practice: the example of the second generation "atypical" antipsychotics. Schizophr Bull 2003;29(1):105-14.

Jones H, Pilowsky L. Dopamine and antipsychotic drug action revisited. British Journal of Psychiatry 2002;181:271-5.

Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001;50(11):873-83.

Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001;158(3):360-9.

Keen M. Get on the right track with Z-track injections. Nursing 1990;20(8):59.

Kemp R, Hayward P, Applewhaite G, Everitt B, David A. Compliance therapy in psychotic patients: randomised controlled trial. Bmj 1996;312(7027):345-9.

Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59(11):1021-6.

Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160(7):1209-22.

Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361(9369):1581-9.

MacGabhann L. Improvements in nursing practice through a study comparing intramuscular depot injection administration techniques. J Psychiatr Ment Health Nurs 1997;4(6):436-7.

MacGabhann LM. A comparison of 2 depot injection techniques. Nursing Standard 1998;12(June):39-41.

McCabe R, Heath C, Burns T, Priebe S. Engagement of patients with psychosis in the consultation: conversation analytic study. Bmj 2002;325(7373):1148-51.

Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60(1):82-91.

Moore H, West AR, Grace AA. The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia. Biol Psychiatry 1999;46(1):40-55.

NICE. Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care. 2002.

Quartermaine S, Taylor R. A comparative study of depot injection techniques. Nurs Times 1995;91(30):36-9.

Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47(1):27-38.

Shepherd MJ, Swearington PL. Z-track injections. A step-by-step how-to for an underused IM technique. Am J Nurs 1984;84(6):746-7.

Tauscher J, Kapur S. Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies. CNS Drugs 2001;15(9):671-8.

Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev 2002(2):CD000076.

Vass A. NICE guidance "a real victory" for people with schizophrenia. National Institute for Clinical Excellence. Bmj 2002;324(7351):1413.

Wirshing DA, Pierre JM, Erhart SM, Boyd JA. Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatr Clin North Am 2003;26(1):165-90.

Wong DL. Significance of dead space in syringes. Am J Nurs 1982;82(8):1237.

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000;157(4 Suppl):1-45.

Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003;361(9360):799-808.

Appleby L, Warner R, Whitton A, Faragher B. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. Bmj 1997;314(7085):932-6.

Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. Jama 1994;271(12):918-24.

Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60(4):392-400.

Cooper PJ, Murray L. Postnatal depression. Bmj 1998;316(7148):1884-6.

Edwards JG. Long term pharmacotherapy of depression. Can reduce relapses and recurrences in major depression. Bmj 1998;316(7139):1180-1.

Fidge J. Moclobemide and paroxetine (letter). Aust Prescr 1998;21(3):60.

[full text]

Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20(6):607-14.

Gamble D, Thakore J. Long term pharmacotherapy of depression. Tricyclic antidepressants should not be first line treatment. Bmj 1998;317(7166):1157; author reply 8.

Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361(9358):653-61.

Grounds D. Antidepressant wash-out periods (letter). Aust Prescr 1999;22(1):3-4.

[full text]

Johnson G. Which antidepressant? Modern Medicine 1999; 24-7.

Mitchell PB, Malhi GS. The expanding pharmacopoeia for bipolar disorder. Annu Rev Med 2002;53:173-88.

Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999;156(5):702-9.

Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159(6):1011-7.

Trindade EM. Selective serotonin reuptake inhibitors (SSRIs) for major depression. Canadian Coordinating Office for Health Technology Assessment; 1997 August.

Van der Wurff FB, Stek ML, Hoogendijk WL, Beekman AT. Electroconvulsive therapy for the depressed elderly. Cochrane Database Syst Rev 2003(2):CD003593.

Catalan J, Gath D, Edmonds G, Ennis J. The effects of non-prescribing of anxiolytics in general practice. I. Controlled evaluation of psychiatric and social outcome. Br J Psychiatry 1984;144:593-602.

Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003;160(4):749-56.

Stein DJ, Zungu-Dirwayi N, van Der Linden GJ, Seedat S. Pharmacotherapy for posttraumatic stress disorder. Cochrane Database Syst Rev 2000(4):CD002795.

Bocca ML, Le Doze F, Etard O, Pottier M, L'Hoste J, Denise P. Residual effect of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades. Psychopharmacology (Berl) 1999;143(4):373-9.

Doghramji K, Mitler MM, Sangal RBS, C.Taylor, S. Walsleben, J. Belisle, C.Erman, M.K. Hayduk, R. Hosn, R. O'Malley, E.B. Sangal, J.M. Schutte S.L. Yiuakim J.M. A normative study of the maintenance of wakefulness test (MWT). Electroencephalogr Clin Neurophysiology 1997;103(5):554-62.

Earley CJ, Yaffee JB, Allen RP. Randomized, double-blind, placebo-controlled trial of pergolide in restless legs syndrome. Neurology 1998;51(6):1599-602.

Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002;59(10):1573-9.

Littner M, Johnson SF, McCall WV, Anderson WM, Davila D, Hartse SK, et al. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 2001;24(4):451-66.

Mitler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep 1994;17(4):352-71.

Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999;52(5):938-43.

Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry 1994;151(8):1172-80.

Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF, 3rd, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. Jama 1997;278(24):2170-7.

Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T. Tolerance to daytime sedative effects of h1 antihistamines. J Clin Psychopharmacol 2002;22(5):511-5.

Smith MT, Perlis ML, Park A, Smith MS, Pennington J, Giles DE, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 2002;159(1):5-11.

Staedt J, Wassmuth F, Ziemann U, Hajak G, Ruther E, Stoppe G. Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa. J Neural Transm 1997;104(4-5):461-8.

Suhner A, Schlagenhauf P, Hofer I, Johnson R, Tschopp A, Steffen R. Effectiveness and tolerability of melatonin and zolpidem for the alleviation of jet lag. Aviat Space Environ Med 2001;72(7):638-46.

Wetter TC, Stiasny K, Winkelmann J, Buhlinger A, Brandenburg U, Penzel T, et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 1999;52(5):944-50.

Gunderson JG. Borderline personality disorder: a clinical guide. Washington DC: American Psychiatric Press; 2001.

Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Fluoxetine Bulimia Nervosa Collaborative Study Group. Arch Gen Psychiatry 1992;49(2):139-47.

American Psychiatric Association. Practice guideline for the treatment of patients with eating disorders (revision). American Psychiatric Association Work Group on Eating Disorders. Am J Psychiatry 2000;157(1 Suppl):1-39.

Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa. The Cochrane Library, Issue 3, 2003. Oxford: Update Software. 2001(4):CD003391.

Bacaltchuk J, Hay PJ. Antidepressants versus psychological treatments and their combination for bulimia nervosa. The Cochrane Library, Issue 3, 2003. Oxford: Update Software. 2003.

Beumont PJ, Russell JD, Touyz SW, Buckley C, Lowinger K, Talbot P, et al. Intensive nutritional counselling in bulimia nervosa: a role for supplementation with fluoxetine? Aust N Z J Psychiatry 1997;31(4):514-24.

Brownell K, Fairburn CG. Eating disorders and obesity: a comprehensive handbook. New York: Guilford Press; 1995.

Fairburn C, Marcus M, Wilson G. Cognitive-behavioural therapy for binge eating and bulimia nervosa: a comprehensive treatment manual. In: Binge eating: nature, assessment and treatment. New York: Guilford press; 1993.

Fairburn CG, Norman PA, Welch SL, O'Connor ME, Doll HA, Peveler RC. A prospective study of outcome in bulimia nervosa and the long-term effects of three psychological treatments. Arch Gen Psychiatry 1995;52(4):304-12.

Garfinkel P, Walsh BT. Drug therapies. 2nd ed. New York: Guilford Press; 1997.

Garner D, Garfinkel P. Handbook of treatment for eating disorders. 2nd ed. New York: Guilford Press; 1997.

Gilchrist PN, Ben-Tovim DI, Hay PJ, Kalucy RS, Walker MK. Eating disorders revisited. I: Anorexia nervosa. Med J Aust 1998;169(8):438-41.

Hay PJ, Gilchrist PN, Ben-Tovim DI, Kalucy RS, Walker MK. Eating disorders revisited. II: Bulimia nervosa and related syndromes. Med J Aust 1998;169(9):488-91.

Hay P, Bacaltchuk J. Bulimia nervosa. Clin Evid 2003(9):997-1009.

Hay PJ, Bacaltchuk J. Psychotherapy for bulimia nervosa and binging. The Cochrane Library, Issue 3, 2003. Oxford: Update Software. 2003.

Hudson JI, McElroy SL, Raymond NC, Crow S, Keck PE, Jr., Carter WP, et al. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am J Psychiatry 1998;155(12):1756-62.

Sharp CW, Freeman CP. The medical complications of anorexia nervosa. Br J Psychiatry 1993;162:452-62.

Treasure J, Schmidt U. Anorexia nervosa. Clin Evid 2003(9):986-96.

Wheadon DE, Rampey AH, Jr., Thompson VL, Potvin JH, Masica DN, Beasley CM, Jr. Lack of association between fluoxetine and suicidality in bulimia nervosa. J Clin Psychiatry 1992;53(7):235-41.

A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999;56(12):1073-86.

Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med 2001;344(17):1279-85.

Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002;159(8):1337-46.

Barkley R. Major life activity and health outcomes associated with attention deficit/hyperactivity disorder. J Clin Psychiatry in press (2003).

Bruggeman R, van der Linden C, Buitelaar JK, Gericke GS, Hawkridge SM, Temlett JA. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 2001;62(1):50-6.

Dion Y, Annable L, Sandor P, Chouinard G. Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2002;22(1):31-9.

Einfeld S. Systematic management approach to pharmacotherapy for people with learning disabilities. Advances in Psychiatric Treatment 2001;7:43-495.

Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002;41(10):1205-15.

Fonagy P, Target M, Cottrell, Phillips J, Kurtz Z. What works for whom? A critical review of treatments for children and adolescents. London: The Guilford Press; 2002.

Gaffney GR, Perry PJ, Lund BC, Bever-Stille KA, Arndt S, Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 2002;41(3):330-6.

Geller B, Cooper TB, Sun K, Zimerman B, Frazier J, Williams M, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry 1998;37(2):171-8.

Geller B, Reising D, Leonard HL, Riddle MA, Walsh BT. Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999;38(5):513-6.

Greenhill LL, Halperin JM, Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry 1999;38(5):503-12.

Greenhill L. Psychopharmacology of ADHD. In: American Academy of Child Psychiatry; 2002; San Francisco; 2002.

Hazell P, O'Connell D, Heathcote D, Robertson J, Henry D. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. Bmj 1995;310(6984):897-901.

Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001;40(7):762-72.

Kowatch RA, Suppes T, Carmody TJ, Bucci JP, Hume JH, Kromelis M, et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2000;39(6):713-20.

Kurlan R. Methylphenidate to treat ADHD is not contraindicated in children with tics. Mov Disord 2002;17(1):5-6.

Kutcher S. Practical child and adolescent psychopharmacology: Cambridge University Press; 2002.

Law SF, Schachar RJ. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry 1999;38(8):944-51.

McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347(5):314-21.

Prince JB, Wilens TE, Biederman J, Spencer TJ, Millstein R, Polisner DA, et al. A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2000;10(3):193-204.

Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001;158(12):2008-14.

Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003;60(7):1130-5.

Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002;41(9):1026-36.

Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. Jama 2003;290(8):1033-41.

Begg EJ, Duffull SB, Saunders DA, Buttimore RC, Ilett KF, Hackett LP, et al. Paroxetine in human milk. Br J Clin Pharmacol 1999;48(2):142-7.

Croke S, Buist A, Hackett LP, Ilett KF, Norman TR, Burrows GD. Olanzapine excretion in human breast milk: estimation of infant exposure. Int J Neuropsychopharmacol 2002;5(3):243-7.

Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry 2002;63 Suppl 4:42-55.

Gardiner SJ et al. Transfer of olanzapine into human milk, calculated infant dose and effects in breastfed infants. Am J Psychiatry in press.

Gjere NA. Psychopharmacology in pregnancy. J Perinat Neonatal Nurs 2001;14(4):12-25.

Ilett KF, Hackett LP, Dusci LJ, Roberts MJ, Kristensen JH, Paech M, et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. Br J Clin Pharmacol 1998;45(5):459-62.

Ilett KF, Kristensen JH, Hackett LP, Paech M, Kohan R, Rampono J. Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants. Br J Clin Pharmacol 2002;53(1):17-22.

Kristensen JH, Ilett KF, Dusci LJ, Hackett LP, Yapp P, Wojnar-Horton RE, et al. Distribution and excretion of sertraline and N-desmethylsertraline in human milk. Br J Clin Pharmacol 1998;45(5):453-7.

Kristensen JH, Ilett KF, Hackett LP, Yapp P, Paech M, Begg EJ. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol 1999;48(4):521-7.

Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Addit Contam 2003;20(1):1-30.

Rampono J, Kristensen JH, Hackett LP, Paech M, Kohan R, Ilett KF. Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants. Br J Clin Pharmacol 2000;50(3):263-8.

SIGN, Scottish Intercollegiate Guidelines Network. Postnatal depression and puereral psychosis. 2002.

[Full text]

Stewart DE. Antidepressant drugs during pregnancy and lactation. Int Clin Psychopharmacol 2000;15 Suppl 3:S19-24.